Akdeniz University
Antalya, Konyaaltı, 07070, Turkey (Türkiye)
NCT Number: NCT06807047
The aim of this study was to determine the effects of the training given to the teachers of children with intellectual disabilities with the "Epilepsy Management at School Mobile Health Application" and the "Digital Epilepsy Education Guide" on teachers' epilepsy knowledge, attitudes, and self management levels. This study was planned in a pretest, posttest design, follow-up, randomized controlled study. The sample of the study will consist of 90 teachers. Intervention-1 (Epilepsy Management at School Mobile Health Application, n=30), intervention-2 (Digital Epilepsy Education Guide, n=30) and control group (group without any intervention, n=30) will be included in the study. The data collection tools to be used in the research will be applied to all three groups at the same time intervals (T0: Just before the application phase of the research, T1: 15 days after the application, T2: one month after the application). The data will be collected using the Personal Information Form, the Knowledge and Attitudes Toward Epilepsy Among School Teachers Scale, and the Epilepsy Self-Management Scale for Teachers. Statistical Package for the Social Sciences (SPSS) 25.0 package program will be used in the analysis of the data.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Antalya, Konyaaltı, 07070, Turkey (Türkiye)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Teachers who meet the inclusion criteria will use the EpiSchool
Teachers who meet the inclusion criteria will use the EpiGuide
Time frame: 1.5 months
The scales developed by Kos et al. (2023) assess knowledge and attitudes toward epilepsy. A higher total score indicates a higher level of knowledge and attitude. The scales consist of two parts: the "Attitudes Toward Epilepsy Among School Teachers Scale" and the "Knowledge Toward Epilepsy Among School Teachers Scale." The "Attitudes Toward Epilepsy Among School Teachers Scale" has two subdimensions: attitudes toward social relationships of children with epilepsy (10 items) and attitudes toward epilepsy-related limitations (5 items), totaling 15 items. A lower score on this scale indicates more positive attitudes toward epilepsy.
The "Knowledge Toward Epilepsy Among School Teachers Scale" includes two subdimensions: knowledge about epilepsy (2 items) and knowledge about epilepsy's effects (10 items), totaling 12 items. A lower score on this scale indicates higher knowledge about epilepsy.
Both scales are five-point Likert-type measurement tools.
Time frame: 1.5 months
The Epilepsy Self-Management Scale for Teachers, developed by Kos et al. (2022), aims to assess epilepsy self-management in teachers. It is a 23-item, five-point Likert scale. Responses are numbered from 1 to 5, with 1 meaning "Never" and 5 meaning "Always." Each item on the scale can receive a score between 1 and 5. The scale consists of three subdimensions: the first subdimension is seizure-related self-management (13 items), the second subdimension is pre-seizure self-management (5 items), and the third subdimension is post-seizure self-management (5 items).
Kafkas University
Other
The Effect of Epilepsy Management at School Mobile Health Application on Epilepsy Knowledge, Attitudes, and Self-Management of Teachers of Children With Intellectual Disability: A Randomized Controlled Study
Acronym: EpiSchool-M
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03847753
Acquired Immunodeficiency Syndrome, Allergy
View Trial DetailsNCT04337697
Brain Damage, Chronic, Brain Diseases
San Francisco, California, United States
View Trial DetailsNCT06402526
Anxiety, Anxiety Disorders
Montreal, Quebec, Canada
View Trial DetailsNCT07090980
Behavior, Brain Diseases
Istanbul, gaziosmanpaşa, Turkey (Türkiye)
View Trial Details